All In MedTech

FDA Clearance Tracker · P150031-S064

Vercise PC DBS System, Vercise Gervia DBS System, Vercise Genus DBS System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Feb 29, 2024 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Feb 29, 2024

Approved

Time to decision

153 days

Received Sep 29, 2023. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P150031-S064
Device name
Vercise PC DBS System, Vercise Gervia DBS System, Vercise Genus DBS System
Applicant location
Valencia, CA
Received
Sep 29, 2023
Decided
Feb 29, 2024
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P150031

Device type

Device class
Class III

Every decision under product code NHL

FDA's approval statement

As written in FDA's record.

Expanding the current indications for use (IFU) to include “Bilateral stimulation of the ventral intermediate nucleus (VIM) of the thalamus for the suppression of disabling upper extremity tremor in adult essential tremor patients whose tremor is not adequately controlled by medications and where the tremor constitutes a significant functional disability”

Source documents

Other decisions for Boston Scientific Corp

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.